Telmisartan information from DrugsUpdate
L - Contraindicated in lactation
FI - Food *
Telmisartan is an angiotensin II receptor antagonist (ARB) used in the management of hypertension. It is marketed under the trade names Telminorm (by Ipca), Pritor or Kinzal (Bayer Schering Pharma), Micardis (Boehringer Ingelheim), Telma (Glenmark Pharma), Telday (Torrent Pharmaceuticals) and Teleact D by (Ranbaxy).
Telmisartan is in a group of drugs called angiotensin II receptor antagonists. Telmisartan keeps blood vessels from narrowing, which lowers blood pressure and improves blood flow.
Telmisartan is used to treat high blood pressure (hypertension). It is sometimes given together with other blood pressure medications.
Telmisartan is also used to reduce the risk of stroke, heart attack, or death from heart problems in people who are at least 55 years old with risk factors for serious heart disorders.
Telmisartan is a nonpeptide AT1 angiotensin II receptor antagonist. Exerts antihypertensive activity by preventing angiotensin II from binding to AT1 receptors thus inhibiting the vasoconstriction and aldosterone-secreting effects of angiotensin II.
Rapidly absorbed. Dose dependent bioavailability 42% (after 40 mg dose); 58% (after 160-mg dose). Peak plasma concentrations: 0.5-1 hours.
Protien binding: 99%.
Undergoes conjugation with glucuronic acid to form inactive metabolites.
Excreted almost entirely as unchanged drug in faeces via bile. <1% excreted via urine. Terminal elimination half-life: 24 hours.
Information Not Available
URTI, dizziness, back pain, sinusitis, pharyngitis and diarrhoea. Slight elevations in liver enzymes.
Potentially Fatal: Rarely angioedema, rash, pruritus and urticaria.
When used in pregnancy during the second and third trimesters, drugs that act directly on the renin-angiotensin system can cause injury and even death to the developing fetus. When pregnancy is detected, discontinue therapy as soon as possible.
Hypotension, dizziness, tachycardia or bradycardia. Supportive treatment to be instituted. Not removed by haemodialysis.
Hepatic insufficiency, biliary obstruction, renal impairment, renaly artery stenosis. Correct volume depletion before initiating treatment. Monitor serum potassium levels regularly, especially in elderly and renally-impaired patients.
Concurrent use increases digoxin concentration; increases risk of lithium toxicity; increases risk of hyperkalaemia with potassium sparing diuretics, heparin.
Food slightly reduces the bioavailability
Adult: Initially, 40 mg once daily. Max: 80 mg/day.
Renal impairment: Severe impairment/ Haemodialysis: Initial dose 20 mg/day.
Hepatic impairment: Mild to moderate: Max 40 mg/day. Severe: Contra-indicated
May be taken with or without food
List of Contraindications
Contraindicated in pregnancy
Category C: Either studies in animals have revealed adverse effects on the foetus (teratogenic or embryocidal or other) and there are no controlled studies in women or studies in women and animals are not available. Drugs should be given only if the potential benefit justifies the potential risk to the foetus.
In 2nd & 3rd trimesters.
Category D: There is positive evidence of human foetal risk, but the benefits from use in pregnant women may be acceptable despite the risk (e.g., if the drug is needed in a life-threatening situation or for a serious disease for which safer drugs cannot be used or are ineffective).
Contraindicated in lactation
Safety and efficacy not established
Severe hepatic impairment, biliary obstructive disorders. Pregnancy. Lactation.
Store at 15-30°C
Telmisartan brands in India